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Abstract 
The purpose of the study was to assess the stoichiometries of phosphate precipitates and determine the 
intrinsic solubilities, S0, of 25 basic drugs from their published solubility-pH profiles in the landmark study 
of Bergström et al. (2004), where 0.15 M phosphate buffer media had been used. A secondary purpose of 
this study was to attempt to predict phosphate 1:1 and 2:1 solubility products, Ksp, from knowledge of S0.  
The published data have been re-analyzed using a novel solubility-pH analysis computer program, 
pDISOL-X
TM
.  The program internally derives implicit solubility equations, given a set of proposed equilibria 
and constants (which are then iteratively refined by weighted nonlinear regression), and does not require 
explicit Henderson-Hasselbalch equations. The data were tested for the presence of phosphate 
precipitates of various stoichiometries, as well as the simultaneous presence of aggregated species, either 
cationic or neutral. The presence of particular species was suggested by the slope characteristics of the log 
S vs. pH curves. Considerably different intrinsic solubility constants were found, compared to those 
originally reported, for several drugs (e.g., celiprolol, desipramine, haloperidol). The least soluble 
molecule, amiodarone, analyzed to have the extraordinarily low intrinsic solubility of 2 picograms/mL, a 
moderate salt solubility of 0.82 mg/mL at the Gibbs-pKa 5.4, corresponding to the species BH∙H2PO4(s), and 
a substantial presence of the positively-charged pentameric aggregate, (BH)5.   
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Introduction 
When sparingly soluble basic drugs are added in substantial amount to phosphate-containing buffer 
solutions, there is likelihood that some drugs will precipitate as phosphate salts in neutral or acidic 
solutions.  Because the buffer can exist in three negatively charged overlapping forms in solution, different 
phosphate precipitates can form with positively charged ionizable drugs. The process is influenced by the 
solution pH in relation to the pKa of the drug.  If an appreciable amount of chloride is also present in 
solution, drug-chloride precipitates may form in lieu of, or along with phosphate precipitates.  
Furthermore, in parallel to precipitation, formation of water-soluble oligomeric drug and micelle species 
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can substantially complicate the interpretation of the solubility measurements, especially when the drugs 
have more than one pKa.   
Although such systems had been studied on a specific case-by-case basis, general computational 
approaches suitable to tackle the above complexity had been scarce. Perhaps as a result, the need for such 
analyses had not been widely appreciated. Yet, quantitative analysis of such complex reactions clearly 
would have beneficial impact in early drug development in terms of clearer interpretations of mechanistic 
dissolution studies involving salts of sparingly soluble drugs in complex media with which the drugs can 
directly interact (e.g., such as simulated intestinal fluids) [1-5]. Since salt solubility is a conditional constant, 
depending on the drug and the specific counterion concentrations, the determination of the 
thermodynamic solubility product allows for scalability of salt effects across a wide range of concentrations 
of substituents in formulation research.  In addition, the formation of drug aggregates can have significant 
impact on measured in vitro permeability, since aqueous diffusivity of compounds depends on their size,  
e.g., as was suggested in the Caco-2 study of retinoic acid in neutral solution [6].      
There are numerous reports of aggregation forming systems [1,5-12]. For example, doxycycline [8], with 
intrinsic solubility S0 0.72 mg∙mL
-1, at 25 °C in 1 M NaCl/HCl acidic solutions, forms dimers with K2 = 24 M
-1. 
Such aggregates were found to have unusually high solubility, sensitively dependent on temperature.  Zhu 
and Streng [9] found that the self-association of dolasetron to form cationic dimers and trimers was 
enthalpy driven (H-bond/aromatic ring rather than hydrophobic/electrostatic interactions), with the 
aggregation constants, K2-3, ranging from 4 to 50 M
-1
 at 25 °C. Many nonsteroidal antiinflammatory drugs 
[10], such as indomethacin, diclofenac, ibuprofen, ketoprofen, naproxen, and sulindac, can self-associate 
by forming mixed-charge micelle or micelle-like structures. The reported CMC of diclofenac is about 25 mM 
and of ketoprofen is about 160 mM [10]. The re-analysis of the data of Higuchi et al. [7] indicated that 
barbital and phenobarbital likely formed anionic dimers (reaching peak concentrations near pH 8), whereas 
oxytetracycline showed a pronounced tendency to form a cationic dimer (peaking near pH 2) [11]. 
Saturated alkaline solutions of diprenorphine (pH > 9) appeared to suggest the formation of a mixed-
charge anionic dimer [12]. In these and many other similar studies, it is evident that the solubility-pH 
profiles cannot be described accurately with the Henderson-Hasselbalch equation when aggregates form 
[1,5,11-13]. 
This manuscript is the third contribution in a series of studies applying a new salt solubility analysis, 
refinement, and simulation computer program, pDISOL-XTM (in-ADME Research), to the study of non-
Henderson-Hasselbalch behaving solubility systems [11,12]. The main objective of this brief commentary is 
to assess the stoichiometries of phosphate precipitates and determine the intrinsic solubilities, S0, of 25 
basic drugs from their published solubility-pH profiles in the landmark study of Bergström et al. [13], where 
0.15 M phosphate buffer media had been used. A parallel purpose of the study was to attempt to predict 
the 1:1 and 2:1 phosphate solubility products, Ksp, from knowledge of S0, something that had not been 
done hitherto, as far as we know. 
Experimental  
Legacy Data 
In the Bergström et al. [13] study, the solubility experiments were performed at 23 °C, using a 
miniaturized shake flask method. Each drug was added in excess to 0.05-0.2mL of 0.15 M phosphate 
buffer.  The pH of each drug suspension was then adjusted using solutions of H3PO4 or KOH to a selected 
pH (in some cases as low as 1.5 and as high as 12). The suspensions were then agitated at 300 rpm on a 
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plate shaker for 24 h, the assigned equilibration time. After 24 h, the samples were centrifuged to separate 
the precipitate from the solution. The drug concentration in the supernatant was analyzed by HPLC 
(UV/fluorescence detection). Light scattering measurements did not find colloidal particulates or 
agglomerates in the supernatant. Practically insoluble amiodarone, carvedilol and mifepristone could not 
be detected directly by HPLC. Subsequently, these drugs were studied in 6 – 24 % w/w methanol-water 
mixtures. The corresponding intrinsic solubilities, S0, were determined by extrapolation of the water-
cosolvent solubilities to zero cosolvent.  In most cases, the value of S0 was assigned to the drug solubility at 
pH ≈ pKa + 2, where the drug was expected to be predominantly uncharged. The assays appeared to be 
well designed. However, it would have been helpful presently to have access to the actual amounts of drug 
added per mL of buffer in the original study. In addition, it is plausible that some of the practically insoluble 
drugs had not reached true thermodynamic equilibrium in 24 h. This could be a topic of further study.   
 
Refinement of Intrinsic and Salt Solubility and Aggregation Constants 
The new data analysis method uses log S - pH as measured input data (along with the standard 
deviations in log S) into the pDISOL-X computer program, as described previously [11,12]. Solubility values 
from literature sources are converted to molarity units for processing by the program. Briefly, an algorithm 
was developed which considers the contributions of all species present in solution, including all 
components of buffers or mixtures thereof. The approach does not depend on any explicitly derived 
extensions of the Henderson-Hasselbalch equations [1]. The uniqueness of the computational algorithm is 
that it derives its own implicit equations internally, given any practical number of equilibria and estimated 
constants, which are subsequently refined by weighted nonlinear least-squares regression. Drug-salt 
precipitates, -aggregates, -complexes, - bile salt and -surfactant species can be modeled [1,5]. The presence 
of specific buffer-drug formed species can be tested. The computer program calculates the distribution of 
species corresponding to a sequence of additions of standardized strong-acid titrant HCl (or weak-acid 
titrants, e.g., H3PO4) to simulate the speciation in the suspension down to pH ~ 0. Subsequently, a 
sequence of perturbations with standardized NaOH (or, e.g., KOH) is simulated, and solubility calculated at 
each point (in pH steps of 0.005-0.2), up to pH ~ 13. The ionic strength is rigorously calculated at each step, 
and pKa values (as well as solubility products, aggregation constants) are accordingly adjusted [11].  At the 
end of the speciation simulation, the calculated log S vs. pH curve is compared to actual measured log S vs. 
pH. A log S-weighted nonlinear least squares procedure refines the proposed equilibrium model, using 
analytical expressions for the differential equations. The process is repeated until the differences between 
calculated and measured log S values reach a minimum, as described elsewhere in detail [11]. 
The analysis of the Bergström log S - pH data tested for the presence of solid species B(s), BH∙Cl(s), 
BHB∙Cl(s), BH∙H2PO4(s), (BH)2∙HPO4(s),  BHB∙H2PO4(s), (BHB)2∙HPO4(s), (BH)3∙H2PO4∙HPO4(s), as well as water 
soluble cationic aggregates (BH)n and (BHB)n, n = 1-6, and the uncharged aggregate B2. Up to three different 
solids could be tested in a single calculation. The presence of particular species was suggested by the slope 




Avdeef  ADMET & DMPK 2(1) (2014) 43-55 
46  
Results and Discussion 
Based on the results of the analysis, the 25 drugs were divided into six groups, according to the type of 
deviations from the Henderson-Hasselbalch equation in the non-salt regions (pH > pKa
GIBBS [14,15]) of the 
log S – pH curves, as discussed at length by Avdeef [1]. 
 CASE 0 (24 % of all drugs): follow Henderson-Hasselbalch equation, and apparent S0 = true S0.  
 CASE 1b (24 %): apparent pKa < true pKa and apparent S0 > true S0, which is consistent with the 
formation of water-soluble uncharged aggregates; degree of aggregation cannot be determined from 
pH-dependence.     
 CASE 2b (16 %): diagonal region of the log S – pH profile has non-unit slope, indicative of cationic 
aggregates, where the average degree of aggregation defined by the value of the slope; apparent S0 = 
true S0. 
 CASE 3b (16 %): diagonal region of the log S – pH profile (slope = -1) shifted to higher pH than predicted 
by Henderson-Hasselbalch equation (i.e., apparent pKa > true pKa), indicative of mixed-charge dimeric 
aggregates, BHB
+
, or higher order oligomers of the same stoichiometric ratio; apparent S0 = true S0. 
 Two group of compounds showed combined CASE 1b+2b (8 %) and CASE 2b+3b (12 %). 
The results of the analysis of the Bergström et al. data are summarized in Table 1, with all constants 
presented in molarity or molarity related units. Figure 1 compares intrinsic solubility, pS0 (-log10 S0), of the 
compounds determined in this study to that reported by Bergström et al. [13]. Amiodarone is not shown in 
Figure 1, since the previously reported value was stated conditionally (Table 1). The eight compounds in 
Figure 1 represented as checkered circles are all examples of CASE 1b, and showed the largest variances 
from the reported intrinsic solubility values. On the other hand, the agreement between the filled circle 
compounds (corresponding to other cases) determined here and reported previously is very good:  
pS0
Bergström = 0.02 + 1.007 pS0 
pDISOL-X, r2=0.99, s=0.17, F=1014, n=16. 
Table 1. Summary of the Results of the Re-Analysis of the Bergstrom et al. [13] Data. 
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CASE 0 – No Aggregation; Henderson-Hasselbalch Equation Accurate for pH > pKa
GIBBS 
Figure 2 shows the six compounds which show no appreciable deviation from the log S – pH curves 
calculated by the Henderson-Hasselbalch equation (non-salt region: pH > pKa
GIBBS). The compounds are 
arranged in the order of decreasing intrinsic solubility. Carvedilol and chlorprothixene indicated the lowest 
intrinsic solubility, with values < 0.5 µg∙mL-1. The most soluble molecule is lidocaine, with S0 = 2.5 mg∙mL
-1.  
The pH at the point of discontinuity between the (most-often flat) salt region and the diagonal slope = -1 
curve is called pKa
GIBBS [14,15]. For example, pKa
GIBBS = 6.2, 9.2, 7.0, 2.9, 6.7, 6.0 for the drugs in Figure 2, in 
the order of their appearance. 
With the exception of verapamil and carvedilol, simple 2:1 and/or 1:1 phosphate salts appear to form 
with this class of compounds. Verapamil data in the salt region (pH < pKa
GIBBS
) are consistent with the 
formation of a chloride salt with the mixed-charge dimer of verapamil, (BHB+)∙Cl-(s). The region below pH 7 
displays a slope = -0.5, characteristic of such a stoichiometry. Carvedilol salt region is best fit with a 
diphosphate stoichiometry: 3 BH+ + H2PO4
- + HPO4
2-   (BH)3H3(PO4)2(s). 
Verapamil and carvedilol (and mifepristone, below) illustrate why it is better to designate the pH of 
discontinuity as pKa
GIBBS, rather than “pHmax,” since the discontinuity can occur at a pH where the solubility 
is not at all at its maximum value [14,15]. 
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Figure 2.  CASE 0 compounds which show Henderson-Hasselbalch form log S – pH curves in the non-salt region. 
 
CASE 1b – Neutral Aggregates; Henderson-Hasselbalch Equation Not Accurate 
 
Figure 3 shows the six compounds with apparent pKa < true pKa, which is consistent with the formation 
of water-soluble uncharged aggregates. The Henderson-Hasselbalch equation does not accurately predict 
the log S – pH curves across the entire pH range. For CASE 1b drugs, the apparent S0 > true S0. The degree 
of aggregation cannot be determined from pH-dependence, since the aggregated compound is in the 
uncharged form. The compounds in Figure 3 are arranged in the increasing order of aggregation strength. 
 
 
Figure 3.  CASE 1b compounds:  log S – pH curve distortions consistent with the formation of neutral aggregates. 
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The compounds in the Figure 3 either (i) form stable water-soluble aggregates of the uncharged drug, or 
(ii) the compounds show a pattern of curve distortion, which is characteristic of a system that had not 
reached a true state of thermodynamic equilibrium at the 24 h time point. That is, neutral aggregates may 
be thermodynamically unstable and are very slowly coalescing into solid form. Examples of the former (i) 
effect have been reported with molecules like piroxicam [1,5], and cases of the latter (ii) effect have been 
reported for terfenadine, which at 24 h showed more pronounced distortion that at 68 h [1,5] (it would be 
useful to repeat the measurements of the six drugs in Figure 3 at much longer equilibration times than the 
24 h actually used). It is evident that to analyze CASE 1b compounds, it is necessary to know the true pKa 
accurately.   
It is with this class of compounds that there were the largest deviations in Figure 1. Apparently, the 
published intrinsic values [13] ascribed the reported intrinsic solubility to the apparent intrinsic values (the 
minimum red (solid) curve value rather than the minimum dashed curve value). The six examples in the 
above figure show flat curves in the salt region, corresponding to simple stoichiometry phosphate or 
chloride salts. 
 
CASE 2b – Cationic Aggregates; Henderson-Hasselbalch Equation Not Accurate 
 
Figure 4 shows four compounds which show non-unit slopes in a part of the diagonal region of the 
log S - pH profile. This is consistent with the formation cationic aggregates. The average degree of 
aggregation is defined by the value of the slope.  Apparent S0 = true S0.    
 
Figure 4.  CASE 2b compounds which show log S – pH curve distortions consistent with the formation of cationic 
aggregates. 
 
Bupivacaine analyzed as consisting of (BH+)2 cationic dimers for pH < 7, co-existing with the 1:1 
phosphate precipitate. This raises the observed solubility in the salt region, due to competition between 
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the drug in the solid and aggregated states. Consequently, greater amount of compound added to solution 
makes the compound more soluble in the salt region. The data shape of the other three molecules was 
most consistent with the presence of pentameric or hexameric cationic aggregates. 
It was possible to rationalize the amiodarone log S – pH profile as being distorted from the shape 
predicted by the Henderson-Hasselbalch equation due to the formation of the pentamer (BH
+
)5. If this were 
a valid interpretation of the data, then there are some very interesting consequences. In the analysis of the 
amiodarone data, it was assumed that 5 mg of drug were added to 1 mL of buffer. The pH < 5 region of 
solubility curve (Fig. 4c) depends on both the presence of the cationic aggregate and the phosphate 
precipitate. Since the concentration of the aggregate depends steeply on the amount of amiodarone added 
to the buffer, a series of simulations with decreasing amounts of amiodarone results in lowering the 
solubility in the salt region. In the extreme, maximum solubility can decrease from about 10-2 (Fig. 4c) to 
10
-7
 M (not shown). This suggests that a parenteral injectable solution can show solubility as high as 5 
mg∙mL
-1
 in the pH 1-5 region, provided enough drug were present in the formulation. However, if a much 
smaller amount of drug were added, then the solubility could be limited by the apparent minimum pKsp,1:1
 
(-log10 Ksp,1:1), to about 14 ng∙mL
-1, with no influence of the aggregate, according to the pDISOL-X simulation 
calculation.   
Amiodarone is the drug of choice in the treatment of arrhythmia, but it has side effects that limit its 
long-term use. In the treatment of chronic arrhythmia, oral doses of amiodarone may take 30 days to 
develop full therapeutic effect because of the extreme hydrophobicity of the drug. Once treatment is 
discontinued, it may take 1-2 months to wash out the drug completely. On the other hand, during recovery 
from heart surgery, the atrium can start to fibrillate dangerously. One remedy is to inject an amiodarone 
parenteral formulation [16] into a vessel carrying blood into the heart. Within a few minutes, the drug can 
take effect. The analysis of the log S – pH profile of amiodarone can shed light on the above two seemingly 
incompatible circumstances.  
Hydralazine was problematic to analyze. Figure 4d shows a red (solid) curve based on the assumed 
presence of a hexameric (BH+)6 species, which is most consistent with the data that deviates most from the 
dashed line in the non-salt region. However, the consequence of such a species being present in parallel 
with the phosphate precipitate is that the pKsp,1:1 would analyze as 5.12 ± 0.24 (the value in Table 1).  
Since the pS0 value is unaffected by the cationic aggregate, the relationship between the Ksp and S0 can be 
dependent on the aggregation model. It will be suggested below that it may be more meaningful to 
assume that the data in the deviation region pH 6-7 is not at equilibrium. When the data are excluded from 
the analysis and no stable aggregate is assumed present, then pKsp,1:1
 analyzes as 2.74 ± 0.04. The latter 
value, which follows the relationship in Figure 8a more closely, was used in the plot and regression 
analysis. 
 
CASE 3b – Mixed-Charge Cationic Dimers; Henderson-Hasselbalch Equation Not Accurate 
Figure 5 shows four examples of CASE 3b log S – pH profiles. These are characterized by the (slope = -1) 
diagonal region of the log S – pH profile shifted to higher pH (i.e., apparent pKa > true pKa) than predicted 
by Henderson-Hasselbalch equation, indicative of mixed-charge dimeric aggregates, BHB+.  In such cases, 
the apparent S0 is the same as the true S0. 
The compounds are arranged in the order of increasing dimerization formation constant, with 
trimethoprim nearly showing Henderson-Hasselbalch characteristic of CASE 0. Mifepristone appears to 
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)(s), characterized by an average 
slope -0.53 ± 0.06 in the pH 1.0 – 3.4 salt region, similar to the case of verapamil (Fig. 2c). Trimethoprim 




Figure 5.  CASE 3b compounds which show log S – pH curve distortions consistent with the formation of mixed-charge 
dimeric aggregates. 
 
Mixtures of Cases; Henderson-Hasselbalch Equation Not Accurate 
Figures 6 and 7 show examples of mixtures of CASE 1b+2b and 2b+3b, respectively. The CASE 1b 
distortion in thioridazine may be due to incomplete equilibration time. 
 
 
Figure 6.  Two examples of compounds showing two overlapping distortion types: CASE 1b (neutral aggregates) and 
CASE 2b (cationic aggregates). 
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Figure 7.  Three examples of compounds showing two overlapping distortion types: CASE 2b (cationic aggregates) and 
CASE 3b (mixed-charge dimers). 
 




Just 18 of the 25 drugs considered were interpreted to include 1:1 BH∙H2PO4 salt formations. The other 
seven drugs were either salts with complicated phosphate stoichiometry or chloride salts (for very soluble 
drugs introduced as hydrochlorides). The average of the ratio values pKsp,1:1 / pS0 is 0.73 ± 0.34.  Figure 8a 
shows the empirical correlation between the pKsp,1:1 constant and the intrinsic solubility pS0 for the 18 
compounds. A trend is evident, in that the less soluble the uncharged form of the drug, the lower is the Ksp 
value. Although the variance is relatively large, the relationship can still be a valuable basis for prediction of 
the phosphate solubility product in the absence of measurement. 
 
 
Figure 8.  (a) Correlations between the 1:1 salt solubility products and the intrinsic solubility constants for 18 of the 
studied compounds.  (b) Correlation between 1:1 and 2:1 drug-phosphate solubility products for 9 of the studied 
compounds.  The bracket concentration products (molarity related units) in the labels have –log10 implied. 
 
Relationship between pKsp,1:1
 and pKsp,2:1 
Nine of the 25 drugs were interpreted to have both 1:1 and 2:1 phosphate salt precipitation.  Figure 8b 
shows an extraordinarily high correlation between the two salt solubility products. This is probably 
expected from equilibrium equation considerations, since the slope of 0.46 is so close to the one-to-two 
ratio of stoichiometries. The average ratio of the two pKsp constants is 0.50 ± 0.04 in Figure 8b. 
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Prediction Equations for Phosphate Salts 
      From the correlation relationships in Figure 8, two useful empirical equations may be derived: 
  pKsp,1:1   = 0.525 + 0.554 pS0         (1) 
pKsp,2:1     = 0.744 + 1.207 pS0  =  -0.4002 +2.1796 pKsp,1:1      (2) 
These equations were used to fill in the “missing” values in Table 1, indicated in red italic numbers. 
 
Chloride Salts  
Since some relatively soluble salts were introduced as drug hydrochlorides, the solubility data were 
tested for the possibility of chloride precipitates. The log S – pH plots for celiprolol, orphenadrine, terazosin 
and pramoxine appeared to be consistent with the formation of 1:1 chloride salts. The salt region in the 
solubility plot is expected to be a horizontal line, since the common ion effect is not expected when the pH 
is adjusted using H3PO4. However, the above assignments are tentative without additional data collected at 
different added amounts of these drugs, especially with data taken to very low pH values.  
 
How Constant Are Solubility Products? 
 
The pDISOL-X program calculates the ionic strength at each pH point in the processing of the log S – pH 
data, as described in detail elsewhere [11]. Figure 9 shows the speciation analysis of disopyramide in the 
phosphate salt region, pH 2 – 9. Figure 9b shows that the ionic strength varies from about 0.1 to 0.4 M as 
the pH changes from 2 to 9. The vertical dotted line near pH 6 in Figure 9a indicates the transition pH 
between the 1:1 and the 2:1 phosphate salts. The ionic strength dependence of the two Ksp constants 
differs, which affects the calculated concentrations. The result of this is that the solubility product above 
pH 6 is not exactly constant, due to the effect of ionic strength. The analysis program is particularly well 
suited to explore the consequences of the choices of various species tested in the solubility model. 
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Evidently, concentrated phosphate buffers (0.15 M) can dramatically influence the solubility profiles of 
sparingly soluble drugs. Clearly, the Bergström et al. [13] data for the 25 compounds studied could not be 
explained by the simple Henderson-Hasselbalch equation in all but six cases. Apparently, the aggregated 
species proposed here were either not recognized originally, or were not fully explored.  Such anomalies 
may be common with sparingly soluble drugs, but are not always easy to recognize. pDISOL-X could be a 
helpful new tool in early development to further aid in the analysis of dissolution mechanisms of sparingly 
soluble drugs, which depend on the stoichiometry and solubility of drug species, especially of salts.  
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